Ads
related to: first line maintenance ovarian cancer- Treatment Effectiveness
Read About How Treatment Works And
Its Benefits And Risks In Patients.
- About PARP Inhibitors
Learn About How Treatment Works.
Learn About Maintenance Therapy.
- Talk To Your Doctor
Get Resources To Help Stay Informed
To Make Your Conversation Easier.
- Safety And Side Effects
Read Important Safety Information.
Learn More About A Treatment.
- First-Line Maintenance
Learn About First-Line Treatment.
Download Helpful Resources & Info.
- Tablet Dosing Info
Learn About Tablet Dosing For
An Ovarian Cancer Treatment.
- Treatment Effectiveness
Search results
Results From The WOW.Com Content Network
In December 2018, olaparib was approved in the United States for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based ...
In the European Union, niraparib is indicated: as monotherapy for the maintenance treatment of adults with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy; and as monotherapy for ...
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
It is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with cisplatin and/or alkylating agent-based combination. [1] It is not considered a first-line treatment, [2] but it can be useful as salvage therapy. [3]
[27] it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer. [28] Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [29] Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 ...
Ovarian cancer's early stages (I/II) are difficult to diagnose because most symptoms are nonspecific and thus of little use in diagnosis; as a result, it is rarely diagnosed until it spreads and advances to later stages (III/IV). [58] Additionally, symptoms of ovarian cancer may appear similar to irritable bowel syndrome.
Ads
related to: first line maintenance ovarian cancer